ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on November 4, 2024, regarding events occurring on that date and effective November 7, 2024. The filing addresses a material modification to the rights of security holders through an amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split Approval: Stockholders approved a reverse stock split at a Special Meeting on October 28, 2024, authorizing a ratio between 1/8 and 1/35.
- Final Ratio Determination: The Board of Directors selected a 1-for-35 reverse stock split ratio.
- Effective Date: The amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on November 4, 2024, becoming effective at 12:01 a.m. Eastern Time on November 7, 2024.
- Trading Adjustments: Common stock will begin trading on a split-adjusted basis on November 7, 2024, under a new CUSIP number (29273B 500).
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the structural change to the capitalization. The primary purpose is to disclose the legal execution of the reverse stock split.
Investor Verification Checklist
- Confirm the 1-for-35 reverse stock split ratio is correctly applied to existing holdings.
- Verify the new CUSIP number (29273B 500) for trading purposes starting November 7, 2024.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional terms regarding fractional shares or rounding.
- Monitor trading volume and price adjustments on the Nasdaq Stock Market following the effective date.